
Evidence analysis
Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study
Burden of bacterial antimicrobial resistance linked to modifiable antibiotic use: An Evidence Dossier This article summarizes findings from a 2026 observational study published in PLOS Medicine investigating the relationship between human antibiotic consumption and bacterial antimicrobial resistance (AMR)…
Read →
Evidence analysis
Outcomes of home-based versus facility-based care for mild diphtheria during a large epidemic in Kano State, Nigeria: A retrospective matched cohort study
Outcomes of Home-Based Versus Facility-Based Care for Mild Diphtheria During a Large Epidemic in Kano State, Nigeria This article summarizes evidence from a retrospective matched cohort study published in PLOS Medicine (October 2026) examining the results of home-based…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Vokanamet, canagliflozin,metformin, Date of authorisation: 23/04/2014, Revision: 26, Status: Authorised
What is established Vokanamet is an authorized diabetes medication in the European Union that combines two active substances: canagliflozin and metformin. It is used to manage blood glucose levels in adults with type 2 diabetes when metformin alone…
Read →
Evidence analysis
Parting words from a scholar who stepped up
What is established Tomiko Brown-Nagin, a noted legal scholar and historian, served as dean of the Harvard Radcliffe Institute for eight years before deciding to become the James Quillen Dean of Stanford University's Graduate School of Education. During…
Read →
Evidence analysis
Position paper on clinical development of Bundibugyo vaccines
Evidence Dossier: Clinical Development of Bundibugyo Ebola Vaccines What is Established Bundibugyo virus is a species of Ebola virus associated with outbreaks of Ebola virus disease (EVD) in humans. Like other Ebola viruses, it causes severe hemorrhagic fever…
Read →
Evidence analysis
AMA and EMA issue joint guidance on Ebola vaccine development
What is established In October 2026, the European Medicines Agency’s Emergency Task Force (EMA’s ETF) and the African Medicines Agency (AMA) jointly published a position paper providing guidance on the development of vaccines targeting Ebola disease caused by…
Read →
Evidence analysis
Threat assessment brief – Importation of Ebola disease cases caused by Bundibugyo virus to Kenya and Nigeria
Threat Assessment Brief: Ebola Disease Caused by Bundibugyo Virus in Kenya and Nigeria (2026) This dossier summarizes evidence from the European Centre for Disease Prevention and Control (ECDC) regarding the importation of Ebola disease cases caused by the…
Read →
Evidence analysis
Smugglers Collected Up to $509M on Europe Routes in 2025
Smugglers’ Revenue from Mediterranean and Atlantic Migration Routes to Europe in 2025: Evidence Dossier What is established New research conducted by the United Nations Office on Drugs and Crime (UNODC) estimates that in 2025, criminal smuggling networks collected…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Date of authorisation: 06/02/2009, Revision: 27, Status: Authorised
What is established Filgrastim Hexal is an authorised biosimilar medicine approved by the European Medicines Agency (EMA). It contains the active substance filgrastim, a recombinant form of human granulocyte colony stimulating factor (G-CSF), which stimulates the production of…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 8, Status: Authorised
What is established Cejemly (active substance: sugemalimab) is a medication authorized by the European Medicines Agency (EMA) for the treatment of non-small cell lung cancer (NSCLC) in adults. It is indicated specifically for: Patients with metastatic NSCLC lacking…
Read →